Thursday, May 23, 2019 7:39:57 AM
$TLTFF-Market indicators for another leg up.
On DEC 18 2018 the prospectus was closed and we saw heavy exercising of warrants coupled with the share price TLTFF moving from .2159 low a few days after the closing to .45 (108% increase) high that presented its self on March 5 2019. After a move like that in market, the stock price behaved normally with traders on the OTCQX grabbing some profits.
-----------------------
Prospectus Withdrawn on May 16, 2019
OSC NOTICE TO PUBLIC ISSUER: Theralase Technologies Inc.
Principal Jurisdiction - Ontario DATES: Preliminary Shelf Prospectus (NI 44-102) dated April 26, 2019
Withdrawn on May 16, 2019
PROJECT NUMBER: 2906418
Currently with the Prospectus withdrawn May 16th, the stock is again engaging he the same dynamics present when the 108%+ increase in share price occurred.
A slight dip in share after the DEC 18 closure.
The short volume in decline.
Multiple near term catalysis ripe for PR.
Evidence of Warrants getting exercised.
JMO... Cheers
On DEC 18 2018 the prospectus was closed and we saw heavy exercising of warrants coupled with the share price TLTFF moving from .2159 low a few days after the closing to .45 (108% increase) high that presented its self on March 5 2019. After a move like that in market, the stock price behaved normally with traders on the OTCQX grabbing some profits.
-----------------------
Prospectus Withdrawn on May 16, 2019
OSC NOTICE TO PUBLIC ISSUER: Theralase Technologies Inc.
Principal Jurisdiction - Ontario DATES: Preliminary Shelf Prospectus (NI 44-102) dated April 26, 2019
Withdrawn on May 16, 2019
PROJECT NUMBER: 2906418
Currently with the Prospectus withdrawn May 16th, the stock is again engaging he the same dynamics present when the 108%+ increase in share price occurred.
A slight dip in share after the DEC 18 closure.
The short volume in decline.
Multiple near term catalysis ripe for PR.
Evidence of Warrants getting exercised.
JMO... Cheers
JMO, maybe, maybe not.
Recent TLTFF News
- Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update • Newsfile • 05/04/2026 09:22:00 PM
- Theralase(R) Closes $CAN 2.66 Million Financing • Newsfile • 04/10/2026 11:00:00 AM
- Theralase(R) Closes $1.1 M Non-Brokered Private Placement • Newsfile • 03/10/2026 11:00:00 AM
- Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer • Newsfile • 03/09/2026 11:00:00 AM
- Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/20/2026 12:00:00 PM
- Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/17/2026 12:00:00 PM
- Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting • Newsfile • 02/10/2026 12:00:00 PM
- Theralase(R) Provides Update on Bladder Cancer Clinical Study • Newsfile • 02/04/2026 12:00:00 PM
- Theralase and Ferring ink deal for new bladder cancer study • IH Market News • 01/14/2026 11:05:00 AM
- New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock • AllPennyStocks.com • 01/12/2026 03:23:00 PM
- Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer • Newsfile • 01/12/2026 12:00:00 PM
- Theralase(R) Closes $1.3 M Non-Brokered Private Placement • Newsfile • 12/23/2025 09:40:00 PM
- Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing • Newsfile • 12/12/2025 10:00:00 PM
- Theralase(R) Investor Conference Call Reminder • Newsfile • 11/17/2025 12:00:00 PM
- Theralase(R) Releases 3Q2025 Financial Statements • Newsfile • 11/10/2025 12:00:00 PM
- Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus • Newsfile • 09/24/2025 11:00:00 AM
